Guardant Health: Partnership Boosts Optimism, Analyst Ratings Soar

Guardant Health's stock surged after a major partnership with Quest Diagnostics to expand access to its Shield cancer screening test, and an improved financial forecast projecting earlier cash flow breakeven. Analysts are bullish, with boosted price targets and reaffirmed Buy ratings, but despite a nearly 93% year-to-date increase, the stock's volatility and past performance suggest cautious optimism. Hosted on Acast. See acast.com/privacy for more information.